BIOMAT Database Logo BIOMAT Database Logo

Age-dependent effect of APOE and polygenic component on Alzheimer's disease. 2020

Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
UK Dementia Research Institute at Cardiff University, Cardiff, United Kingdom.

Alzheimer's disease (AD) is a devastating neurodegenerative condition with significant genetic heritability. Several genes have been implicated in the onset of AD with the apolipoprotein E (APOE) gene being the strongest single genetic risk loci. Evidence suggests that the effect of APOE alters with age during disease progression. Here, we aim to investigate the impact of APOE and other variants outside the APOE region on AD risk in younger and older participants. Using data from both the Alzheimer's Disease Neuroimaging Initiative and the UK Biobank, we computed the polygenic risk score of each individual informed by the latest genetic study from the International Genomics of Alzheimer's Project. Our analysis showed that the effect of APOE on the disease risk is greater in younger participants and reduces as participants' age increases. Our findings indicate the increased impact of polygenic risk score as participants' age increases. Therefore, AD in older individuals can potentially be triggered by the cumulative effect of genes which are outside the APOE region.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000544 Alzheimer Disease A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57) Acute Confusional Senile Dementia,Alzheimer's Diseases,Dementia, Alzheimer Type,Dementia, Senile,Presenile Alzheimer Dementia,Senile Dementia, Alzheimer Type,Alzheimer Dementia,Alzheimer Disease, Early Onset,Alzheimer Disease, Late Onset,Alzheimer Sclerosis,Alzheimer Syndrome,Alzheimer Type Senile Dementia,Alzheimer's Disease,Alzheimer's Disease, Focal Onset,Alzheimer-Type Dementia (ATD),Dementia, Presenile,Dementia, Primary Senile Degenerative,Early Onset Alzheimer Disease,Familial Alzheimer Disease (FAD),Focal Onset Alzheimer's Disease,Late Onset Alzheimer Disease,Primary Senile Degenerative Dementia,Senile Dementia, Acute Confusional,Alzheimer Dementias,Alzheimer Disease, Familial (FAD),Alzheimer Diseases,Alzheimer Type Dementia,Alzheimer Type Dementia (ATD),Alzheimers Diseases,Dementia, Alzheimer,Dementia, Alzheimer-Type (ATD),Familial Alzheimer Diseases (FAD),Presenile Dementia,Sclerosis, Alzheimer,Senile Dementia
D001057 Apolipoproteins E A class of protein components which can be found in several lipoproteins including HIGH-DENSITY LIPOPROTEINS; VERY-LOW-DENSITY LIPOPROTEINS; and CHYLOMICRONS. Synthesized in most organs, Apo E is important in the global transport of lipids and cholesterol throughout the body. Apo E is also a ligand for LDL receptors (RECEPTORS, LDL) that mediates the binding, internalization, and catabolism of lipoprotein particles in cells. There are several allelic isoforms (such as E2, E3, and E4). Deficiency or defects in Apo E are causes of HYPERLIPOPROTEINEMIA TYPE III. Apo-E,Apo E,Apo E Isoproteins,ApoE,Apolipoprotein E Isoproteins,Apoprotein (E),Apoproteins E,Isoproteins, Apo E,Isoproteins, Apolipoprotein E

Related Publications

Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders.
August 2020, Disease models & mechanisms,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Age-dependent effects of APOE ε4 in preclinical Alzheimer's disease.
September 2016, Annals of clinical and translational neurology,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent.
July 1998, Journal of neurology, neurosurgery, and psychiatry,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
ApoE-dependent plasticity in Alzheimer's disease.
January 2004, Journal of molecular neuroscience : MN,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Effect of age, ethnicity, and head injury on the association between APOE genotypes and Alzheimer's disease.
December 1996, Annals of the New York Academy of Sciences,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Genetic risk score modifies the effect of APOE on risk and age onset of Alzheimer's disease.
February 2019, Clinical genetics,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Polygenic Effect on Tau Pathology Progression in Alzheimer's Disease.
April 2023, Annals of neurology,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond APOE.
January 2020, Brain communications,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Age, APOE and sex: Triad of risk of Alzheimer's disease.
June 2016, The Journal of steroid biochemistry and molecular biology,
Eftychia Bellou, and Emily Baker, and Ganna Leonenko, and Matthew Bracher-Smith, and Paula Daunt, and Georgina Menzies, and Julie Williams, and Valentina Escott-Price, and
Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer's disease biomarkers.
November 2022, Aging,
Copied contents to your clipboard!